BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
BET family proteins are epigenetic regulators known to control expression of genes involved in cell growth and oncogenesis. Selective inhibitors of BET proteins exhibit potent anti-proliferative activity in a number of hematologic cancer models, in part through suppression of the MYC oncogene and do...
Saved in:
Main Authors: | Anastasia Wyce, Gopinath Ganji, Kimberly N Smitheman, Chun-Wa Chung, Susan Korenchuk, Yuchen Bai, Olena Barbash, BaoChau Le, Peter D Craggs, Michael T McCabe, Karen M Kennedy-Wilson, Lydia V Sanchez, Romain L Gosmini, Nigel Parr, Charles F McHugh, Dashyant Dhanak, Rab K Prinjha, Kurt R Auger, Peter J Tummino |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/edc29a7e49b54f8688b20ca3340035d5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability
by: Zsuzsanna Nagy, et al.
Published: (2021) -
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
by: Maged Zeineldin, et al.
Published: (2020) -
Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
by: McCabe CF, et al.
Published: (2012) -
Editorial: Molecular Mechanisms and Treatment of MYCN-Driven Tumors
by: Yusuke Suenaga, et al.
Published: (2021) -
“Betting on nature” or “betting on others”: anti-coordination induces uniquely high levels of entropy
by: Gabriele Chierchia, et al.
Published: (2018)